Quantum SI
QSIPre-clinicalFounded in 2013 by Jonathan Rothberg, Quantum-Si is on a mission to power the post-genomic era by democratizing single-molecule protein analysis. Its flagship Platinum Pro instrument and associated kits provide a streamlined workflow for applications ranging from protein identification and variant detection to antibody characterization and ultrasensitive protein detection. As a public company, Quantum-Si is positioned to transform proteomics research and drug development by offering a scalable, benchtop-friendly alternative to mass spectrometry and immunoassays.
QSI · Stock Price
Historical price data
AI Company Overview
Founded in 2013 by Jonathan Rothberg, Quantum-Si is on a mission to power the post-genomic era by democratizing single-molecule protein analysis. Its flagship Platinum Pro instrument and associated kits provide a streamlined workflow for applications ranging from protein identification and variant detection to antibody characterization and ultrasensitive protein detection. As a public company, Quantum-Si is positioned to transform proteomics research and drug development by offering a scalable, benchtop-friendly alternative to mass spectrometry and immunoassays.
Technology Platform
A benchtop next-generation protein sequencing (NGPS) platform that uses single-molecule kinetic signatures to sequence peptides and detect proteins with single-amino-acid resolution, enabling real-time analysis of proteoforms and post-translational modifications.
Opportunities
Risk Factors
Competitive Landscape
Main competitors are mass spectrometry giants (Thermo Fisher, Bruker) and high-sensitivity protein detection firms (Olink, Quanterix). Quantum-Si differentiates through single-molecule, single-amino-acid sequencing capability, real-time kinetic data, a benchtop form factor, and a workflow designed for accessibility without specialized expertise.
Company Info
Trading
Contact
Partners
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile